COVID-19 Vaccine Implications For Corporate Executives

Executive Summary

The emergence of COVID-19 vaccines with a 95% efficacy in clinical trials has provided businesses with new optimism that the end is in sight for the pandemic. This report provides corporate executives in operations, facilities and safety roles with an analysis of these announcements and a framework for business planning in 2021. To better understand what the vaccine developments mean for businesses, Verdantix analysed six promising vaccines and government rollout plans. An optimistic scenario will see the majority of the population inoculated by Q3 2021, but there are notable risks from manufacturing delays, distribution challenges and anti-vax campaigns. Verdantix recommends corporate leaders formulate plans across two time horizons; starting with the next 12 months with COVID-19 still circulating, followed by life beyond the pandemic, with the transition to the next normal.